NASDAQ · Asset Management

Drugs Made In America Acquisition II Corp. Unit (DMIIU) Stock

$10.16 +0.00% NASDAQ: DMIIU Financial Services

DMIIU is a Special Purpose Acquisition Company (SPAC), operating as a blank check firm established in the Cayman Islands. Its core objective is to identify and complete a merger or acquisition with an existing business.

Valuation

MetricValue
Price$10.16
Market Cap$706.57M
P/E Ratio32.77
P/B Ratio—
P/S Ratio—
EPS (TTM)$0.31
52-Week High$10.80
52-Week Low$9.94
Dividend Yield—

Financials & Margins

MetricValue
ROE-22.22%
ROA0.79%
ROCE0.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio0.53

Annual Financials (USD)

Metric2025
Revenue—
Operating Profit$0
Net Profit$4.0M
EPS$0.31
Op Margin—

Balance Sheet (USD)

Metric20242025
Total Assets$0$505.0M
Total Liabilities$0$18.0M
Cash—$0
Borrowings——

Cash Flow (USD)

Metric2025
Operating Cash Flow$-1.0M
Investing Cash Flow$-500.0M
Financing Cash Flow$501.0M
Net Cash Flow$0
Free Cash Flow$-1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-0.14%
Quick Ratio0.52
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held1.07%
Institutions Held6.84%
Institutions Float Held6.91%
Institutional HolderSharesReport Date
LMR Partners LLP2,000,0002026-03-31
Westchester Capital Management, LLC502,9142026-03-31
TIG Advisors, LLC500,0002026-03-31
Verition Fund Management, LLC250,0002026-03-31
BlueCrest Capital Management Ltd250,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
EIC $10.04 +0.70% -210.00 $235.27M 14.22%
GAIN $16.59 -1.60% 3.50 $660.65M 9.19%
GAM $66.33 +0.93% 3.14 $1.59B 10.50%
MSIFMSC Income Fund, Inc. $11.36 -0.61% 6.17 $515.12M 3.17%
NCDL $12.12 -0.57% 10.22 $598.57M 10.46%

About Drugs Made In America Acquisition II Corp. Unit

DMIIU is a Special Purpose Acquisition Company (SPAC), operating as a blank check firm established in the Cayman Islands. Its core objective is to identify and complete a merger or acquisition with an existing business. The company specifically aims to acquire targets within the pharmaceutical and drug industries, driven by the goal of reducing the United States' reliance on international drug manufacturing. Each investment unit comprises one common stock share and an associated right, which entitles the holder to an additional one-tenth of a share once a suitable business combination is successfully finalized.

Drugs Made In America Acquisition II Corp. Unit is headquartered in US.

Drugs Made In America Acquisition II Corp. Unit (DMIIU) stock trades at $10.16 with a market capitalization of $706.57M. The stock is valued at a price-to-earnings (P/E) ratio of 32.77. Over the past 52 weeks the stock has ranged between $9.94 and $10.80, and currently trades 5.9% below its 52-week high.

On profitability, Drugs Made In America Acquisition II Corp. Unit generates a return on equity (ROE) of -22.22%, return on capital employed of 0.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: dmaacorp.com/

Related Financial Services Stocks

BRK.A Insurance - Diversified $733370.00 +0.00% BRK.B FIRE, MARINE & CASUALTY INSURANCE $482.70 +0.00% JPM Banks - Diversified $357.52 +0.34% V Financial - Credit Services $362.50 -2.15% MA Financial - Credit Services $562.95 -2.26% BAC Banks - Diversified $63.17 +0.27% HSBC Banks - Diversified $102.60 -1.06% MS Financial - Capital Markets $203.19 -3.97% GS Financial - Capital Markets $980.75 -5.09% RY Banks - Diversified $206.45 -2.79% WFC Banks - Diversified $83.87 -3.45% MUFG Banks - Diversified $21.94 -2.18%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)Exxon Mobil (XOM)

Screens featuring this stock

High ROE Financial Services StocksLow P/E Financial Services StocksHigh Net Margin Financial Services StocksDividend Financial Services StocksLow Debt Financial Services StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides